Isolation and Characterization of Mammary Stem Cells

This study is currently recruiting participants.

Verified by National Institutes of Health Clinical Center (CC), February 2009

First Received: June 19, 2006 Last Updated: August 24, 2009 History of Changes

Sponsored by:	National Institutes of Health (NIH)
Information provided by:	National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:	NCT00340392

Purpose

Background:

Cancer stem cells in breast cancer have been identified as a small population of tumor cells whose self-renewal mechanism is highly deregulated. This deregulation seems to be necessary for cancer to develop.
These cells can be identified by certain surface markers that overlap with markers associated with normal embryonic stem cells.

Objective: To isolate tumor stem cells using the same methods generally used to isolate human embryonic stem cells.

Eligibility:

Tissue samples will be obtained from the human cooperative network.
Samples will include normal tissues from individuals who have no opportunistic diseases and from individuals with cancer.

Design: Breast cancer stem cells will be isolated, grown in the laboratory and characterized.

Condition
Stem Cells

Study Type:	Observational
Official Title:	Isolation and Characterization of Mammary Stem Cells

Resource links provided by NLM:

MedlinePlus related topics: Cancer

U.S. FDA Resources

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment:	100
Study Start Date:	April 2006
Estimated Primary Completion Date:	March 2009 (Final data collection date for primary outcome measure)

Detailed Description:

Cancers are composed of heterogeneous populations of cells with varying degrees of proliferative capacity and ability to reconstitute tumors when transplanted into nude or SCID mice.

Recently, cancer stem cells have been identified as a small population of tumor cells which possess the stem cell properties in that their self-renewal pathway is highly deregulated. This deregulation seems to be the prerequisite for the development of cancer.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

INCLUSION CRITERIA:

The tissue samples will come from the human cooperative network. They have their own set of criteria. We are requesting tissue samples from individuals that are normal as well as those who have cancer.

EXCLUSION CRITERIA:

The tissue samples will come from the human cooperative tissue network and we are asking for normal samples from individuals who don't have any opportunistic diseases.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00340392

Contacts

Contact: Kimberly Jackson

(301) 435-6305

jacksonki@mail.nih.gov

Locations

United States, Maryland
National Cancer Institute (NCI), 9000 Rockville Pike	Recruiting
Bethesda, Maryland, United States, 20892

Sponsors and Collaborators

National Institutes of Health (NIH)

More Information

No publications provided

Study ID Numbers:	999906140, 06-C-N140
Study First Received:	June 19, 2006
Last Updated:	August 24, 2009
ClinicalTrials.gov Identifier:	NCT00340392 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):

Mammary Stem Cells

ClinicalTrials.gov processed this record on September 11, 2009